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Abstract: Although gut diseases such as inflammatory bowel disease, mucositis and the 
alimentary cancers share similar pathogenetic features, further investigation is required into 
new treatment modalities. An imbalance in the gut microbiota, breached gut integrity, 
bacterial invasion, increased cell apoptosis to proliferation ratio, inflammation and 
impaired immunity may all contribute to their pathogenesis. Probiotics are defined as live 
bacteria, which when administered in sufficient amounts, exert beneficial effects to the 
gastrointestinal tract. More recently, probiotic-derived factors including proteins and other 
molecules released from living probiotics, have also been shown to exert beneficial 
properties. In this review we address the potential for probiotics, with an emphasis on 
probiotic-derived factors, to reduce the severity of digestive diseases and further discuss 
the known mechanisms by which probiotics and probiotic-derived factors exert their 
physiological effects.  
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The microbiota of the gastrointestinal tract in both humans and animals consists of microorganisms 
that flourish throughout the digestive tract. These living microorganisms form an enormous microbial 
community that includes both aerobic and anaerobic bacteria, as well as viruses, fungi and parasites [1]. 
The intestinal microbiota contributes to bowel health in the host by fermenting unused energy 
substrates, preventing growth of harmful pathogenic bacteria [2], and assisting the host immune  
system [3,4]. On the other hand, disordered and impaired microbiota communities are associated with 
conditions such as obesity [5], inflammatory bowel disease (IBD) [6], and critical illness [7]. 
Consequently, it is important to investigate therapeutic strategies aimed at manipulating the dysbiosis 
(disordered microbiobial community) influenced by stressors (disease or other factors). This could 
assist the endogenous microbiota in restoring a normal or more consolidated microbiota status. 
Ingested probiotics (health-promoting bacteria) or their released factors could alter the endogenous 
microbiota to achieve a beneficial balance in the bowel. Together the combined microbiota could 
reduce the severity of certain diseases while preventing others, ultimately improving human health.  
2. Mechanisms of Probiotic Action 
Probiotics are broadly defined as living, non-pathogenic micro-organisms (usually bacteria) which, 
when administered in sufficient numbers, exert a positive influence on host health [8]. Only a minority 
of bacterial species meet this definition. Probiotics are primarily bacteria from the lactobacillus and 
bifidobacterium genera. However, Lactococcus, Streptococcus, and Enterococcus species, as well as 
some non-pathogenic strains of Escherichia coli, and certain bacilli and yeast strains may also act as 
probiotics [9]. The digestive tract is the natural endosymbiotic habitat for probiotic species. In humans, 
lactobacilli and bifidobacteria are commonly present in the vagina, and gastrointestinal tract [10] and 
bifidobacteria are also detectable in the mouth [11]. These probiotics act as commensal bacteria that 
contribute to the maintenance of a healthy intestinal environment.  
A number of animal and human studies have shown the beneficial effects of probiotics on health 
through maintenance of a healthy gut microbiota [12,13]. Some probiotics have the potential to reduce 
the severity of disease conditions ranging from the inflammatory bowel diseases, Crohn’s disease and 
ulcerative colitis, through to forms of cancer [14–16]. To this end, several probiotics have been 
developed for therapeutic purposes [17–19]. In this review, the mechanism of probiotics and the 
efficacy of probiotic-derived factors will be discussed.  
Mechanisms of probiotic action described to date include adhesion to the intestinal-lumen interface; 
competition with pathogens for receptor binding, nutrients and colonization; enhancement of mucosal 
barrier function; promotion of innate and adaptive immune responses; elaboration of bacteriocins; and 
modulation of cell kinetics, with further mechanisms of action likely to be identified [20].  
2.1. Microbiota Composition  
Probiotic administration has the potential to shift the microbiota composition from a pathogenic 
predominance towards a more beneficial microbiotic ecosystem [12,21]. However, due to the  
transient nature of probiotic colonization, of the microbial composition of the microbiota is likely to  
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return to normal if further probiotic administration is ceased. Administration of the probiotic,  
Clostridium butyricum, to healthy broiler chickens over a period of 45 days significantly decreased  
the levels of Escherichia coli, Salmonella and Clostridium perfringens, and concurrently  
increased Lactobacillus, Bifidobacterium and C. butyricum levels in cecal material [12]. Furthermore, 
administration of probiotics (Bifidobacterium and Lactobacillus) for 7 days after elective laparoscopic 
radical surgery in colorectal cancer patients has been shown to (a) significantly restore intestinal 
microbiota composition in fecal samples, as measured by an increase in the levels of Bifidobacterium, 
Lactobacillus, and Enterococcus; (b) reduce counts of Escherichia coli and Staphylococcus aureus [21]. 
2.2. Adhesion as a Mean to Compete with Pathogens 
Adhesion of bacteria to mucosal surfaces and epithelial cells is one of the key features of probiotic 
action [22]. Factors affecting probiotic adhesion include large surface proteins and mucus-binding 
proteins possessing regions homologous with binding domains of proteins such as lectins [23]. The 
lectin-like interactions often result from a number of mucus-binding proteins, such as MUB  
(a cell-surface protein produced by Lactobacillus reuteri encoded a gene from L reuteri 1063) [24]. 
These in turn promote interactions between the bacteria and host gut [23]. For example,  
Lactococcus lactis ssp. lactis BGKP1 has an auto-aggregation phenotype and mucin binding protein 
(MbpL) on its surface, which contributes to its adherence properties in the intestine in vivo and  
in vitro [22]. Moreover, MbpL on the surface of Lactococcus lactis ssp. lactis BGKP1 revealed greater 
binding affinity to gastric-type mucin proteins, such as MUC5AC [22]. In addition, a new surface  
mucin-binding protein, identified on the surface of Bifidobacterium bifidum species and referred to as 
“transaldolase”, has been reported to act as an important colonization factor, potentially assisting 
adhesion of B. bifidum to the gut [25].  
Probiotic adhesion ability is also determined by pH and temperature levels during fermentation [22,26]. 
Deepika et al. have recently reported the adhesion abilities of probiotic Lactobacillus rhamnosus GG 
(LGG) to the intestinal mucosa with different fermentation conditions (pH and temperature), which 
consequently resulted in surface changes during this process [26]. Moreover, some adhesive proteins, 
such as α-enolase, elongation factor Tu (EF-Tu), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
and GroES chaperonin, identified on the LGG surface, have been shown to play an important role in 
the adhesion of LGG to Caco-2 cells [26]. These binding proteins could also be expressed on other 
probiotic bacteria allowing them to participate in the process of probiotic adhesion in the human 
gastrointestinal tract [26]. Studies by Ramiah et al. [27] revealed a similar result. These investigators 
found that the surface-bound proteins, elongation factor Tu (EF-Tu), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and triosephosphate isomerase influenced adhesion of L. plantarum 423 to 
Caco-2 cells and prevented Clostridium sporogenes LMG 13570 and Enterococcus faecalis LMG 
13566 from adhering to Caco-2 cells [27].  
The ability of probiotics to inhibit the growth of pathogens has been widely investigated, and more 
recently, antimicrobial properties of probiotics have been described. Lactobacillus fermentum 202, 
Lactobacillus gallinarum 7001, L. rhamnosus 183, and L. plantarum L2-1 show great potential in vitro 
to inhibit certain intestinal pathogens including Escherichia coli, and Salmonella spp. [28]. 
Escherichia coli strain Nissle 1917 (EcN) has been reported to inhibit the growth of E. coli, 
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Salmonella enterica serovar Typhimurium and Listeria monocytogenes in vitro [29]. Moreover, 
Bifidobacterium breve B632 (DSM 24706), B2274 (DSM 24707), B7840 (DSM 24708) and 
Bifidobacterium longum ssp. longum B1975 (DSM 24709) identified from infant feces also 
demonstrated antimicrobial activity against coliforms and other pathogenic bacteria, while displaying 
no cytotoxic activity against the infant gut epithelium. Consequently, these bacteria could be 
considered as potential probiotics for the treatment and prevention of enteric disorders in  
newborns [30]. Interestingly, Lactobacillus salivarius strain UCC118 triggered the induction of 
antimicrobial genes (CCL20, CXCL1 and CXCL2) in the Caco-2 cell line, providing evidence for the 
antimicrobial capacity of probiotics at the gene level [31]. 
Even though a wide variety of probiotics have demonstrated antimicrobial properties against certain 
pathogens, not all have been shown to be efficacious. For example, Parassol et al. reported that 
Lactobacillus casei DN-114 001 did not inhibit pathogenic EPEC strain adhesion to the human colon 
T84 cell line [32]. This is consistent with the action of the probiotic Lactobacillus paracasei, which 
demonstrated strong adhesion to Caco-2 cells but failed to prevent L. monocytogenes infection [33]. 
Regarding the latter issue, Koo et al. recently have raised a possible explanation. In their studies, 
pathogenic Listeria adhesion protein (LAP)-expressing recombinant probiotic Lactobacillus paracasei 
(Lbp
LAP
) successfully blocked adhesion, invasion, and translocation of Listeria monocytogenes in 
Caco-2 cells [33]. Interestingly, Lbp
LAP
 was also able to prevent L. monocytogenes-mediated cell 
damage, reduce L. monocytogenes-mediated cell cytotoxicity, and restore tight junction integrity [33]. 
Thus, the use of recombinant probiotics that express pathogenic adhesion proteins could be a new 
strategy to prevent pathogenic bacterial infection [33].  
In summary, many probiotics have the ability to adhere to the intestinal-lumen interface; compete 
with pathogens, and perform receptor binding and colonization and hence be beneficial to the host.  
2.3. Maintenance of Intestinal Integrity 
The integrity of the intestinal barrier is influenced by changes in intestinal permeability, mucin 
composition, and homeostasis between the production of new enterocytes and the rate of apoptosis of 
damaged enterocytes. Diseases such as IBD and colon cancer may lead to disruption of the gut  
barrier [34]. Certain probiotics have the potential to modify gut integrity [35–37]. 
2.3.1. Tight Junctions 
Intestinal barrier function is modulated by tight junction (TJ) proteins such as occludin, zonula 
occludens-1, claudin-1, claudin-2, claudin-4, junction adhesion molecule-A and F-actin [37,38]. These 
TJ proteins are located at the sub-apical aspect of the lateral membranes and build the physical 
connections between cells responsible for integrity of the intestinal barrier [37]. However, intestinal 
mucosal barrier dysfunction, in conditions such as inflammatory bowel disease, may lead to increased 
intestinal permeability, which partly results from irregular expression of certain TJ proteins in the 
intestinal epithelium [36,37]. On the other hand, several studies have revealed the capacity for 
probiotics to maintain intestinal barrier function by modifying the expression of TJ proteins. The 
probiotic combination, VSL#3 has been demonstrated to regulate the epithelial TJ protein, occludin, 
and to decrease the expression of claudin-2, subsequently attenuating increased gut permeability  
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in mice with experimentally-induced Crohn’s disease [36]. Similarly, oral administration of  
Lactobacillus plantarum CGMCC No. 1258 enhanced the expression of TJ proteins such as occludin, 
ZO-1, claudin-1, claudin-4 and JAM-A in the intestinal epithelium in both the common bile duct and 
in bile duct ligation challenged rats [37]. In the same study, a relationship was described between 
protein kinase C (PKC) activity and the ability to redistribute TJ proteins in response to L. plantarum 
administration in rats with experimental obstructive jaundice [37]. In addition, these authors concluded 
that the protective ability of L. plantarum on gut barrier was associated with a decrease in intestinal 
epithelial cell apoptosis and a reduction of oxidative stress as evidenced by levels of glutathione, 
malondialdehyde and superoxide dismutase levels in the ileum [37]. 
2.3.2. Mucin Expression 
Integrity of the intestinal microbiota is partly maintained by the structure of mucins [39]. Intestinal 
mucins, the major protein component of mucus coating the epithelium of the gastrointestinal tract, are 
highly glycosylated macromolecules produced by epithelial tissues in most metazoans [40,41]. Goblet 
cells of the enteric epithelium synthesize, store, and secrete mucins to maintain mucus integrity [42]. 
Moreover, mucins form gels and generate a protective mucus blanket overlying the epithelial surface 
to protect the mucosa from bacterial overgrowth [42]. Mucins further create an enormous repertoire of 
potential binding sites for microorganisms [40]. Moreover, it has been reported that certain 
Bifidobacterium bifidum strains can break down glycoprotein linkages within the mucin and facilitate 
colonocyte contact [25]. Hooper et al. elucidated the importance of endogenous microbiota such as 
Bacteroides thetaiotaomicron in assisting the host to degrade indigestible nutrients [43]. This organism 
degraded certain undigested polysaccharides, undigested starch and host-derived glycans, such as 
mucins and glycosphingolipids, to monosaccharides in the colon. These monosaccharides are further 
fermented to result in the production of short chain fatty acids which are utilized by the host as a 
source of energy [43]. 
Luminal toxins and alterations in the intestinal microbiota can cause changes in both goblet cell 
function and the chemical composition of intestinal mucus [44]. In addition, over expression of mucin 
proteins such as MUC1 has been associated with human cancers [45]. Moreover, chemotherapy agents 
affect mucins and goblet cell secretions. For example, the chemotherapy agent, 5-FU, has been 
reported to decrease goblet cell numbers and increase cavitated goblet cells in rats [39]. 
Certain probiotics have the ability to restore intestinal mucin levels. The structural and functional 
properties of mucins influence bacterial adhesion activities. The monosaccharide components of mucin 
carbohydrate side-chains such as N-acetyl-glucosamine (GalNac), galactose (Gal), fucose (Fuc), and 
N-acetyl-neuraminic acid (NeuAc) and their ester sulfates, play an important role in the modulation of 







 colony forming units of probiotic/kg of soybean meal basal (BD) diets) were investigated 
on the composition of intestinal mucin monosaccharides and mucosal morphology in broilers [35]. 
These authors used a probiotic mixture of Lactobacillus reuteri, Enterococcus faecium, 
Bifidobacterium animalis, Pediococcus acidilactici and Lactobacillus salivarius that was able to 
modulate intestinal mucin monosaccharide composition in broilers. Mannose levels decreased linearly 
with increased probiotic levels in the duodenum; and GalNac and Gal levels also decreased, whereas 
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Fuc levels increased with increasing probiotic intake in the cecum of 42-day-old broilers [35]. These 
changes in mucin monosaccharide composition may have resulted from the effects of combinations of 
the different tested probiotics. It is therefore possible that each probiotic strain altered mucin 
monosaccharide composition differentially. In addition, the probiotic mixture increased villus height 
and crypt depth, as well as increasing mucin layer thickness in the duodenum in both 14 day and  
42-day-old broilers [35]. Probiotics can therefore affect the mucosal barrier and influence gut 
microbiota composition and bacterial binding activity through adjusting intestinal mucin 
monosaccharide composition, mucus layer thickness, and intestinal morphology.  
The probiotic Lactobacillus salivarius strain UCC118 has been reported to modulate intestinal cell 
mucin gene production with reduced MUC3A, MUC5AC, and MUC12 gene expression following 
exposure of the UCC118 mutant (lacking sortase-dependent proteins) to Caco-2 cells [31]. Disruption 
of the UCC118 sortase gene srtA decreased the adhesion of bacterial to epithelial cells. It was 
concluded that expression of these mucin genes plays an important role in bacterial adhesion [31]. 
Recently, Hudcovic et al. reported that Clostridium tyrobutyricum, administered 7 days before and 
after induction of colitis by dextran sulphate sodium (DSS) treatment in mice, significantly restored 
MUC-2 mucin depression induced by DSS [34]. Administration of Lactobacillus plantarum Lp91 to 
healthy mice also significantly up-regulated MUC2 gene expression [47].  
In general terms, many probiotics have the potential to normalize intestinal integrity through 
restoration of the mucus layer. This property could be therapeutically important when treating a broad 
range of intestinal disorders and diseases characterized by mucosal injury. 
2.4. Influence on Cell Kinetics  
Certain probiotics are able to modulate cell kinetics through effects on cell proliferation and 
apoptosis. This is important in the homeostasis of cell death and reproduction. Especially, the ability of 
certain probiotics to promote normal cell propagation and concurrently inhibit abnormal cell apoptosis 
could hold potential in the treatment of certain diseases such as cancer.  
2.4.1. Cell Proliferation 
Probiotics may enhance cell proliferation by inhibiting the activity of normal cell apoptosis and  
also by promoting cell differentiation and cytoprotective activities. Lin et al. demonstrated the  
anti-apoptotic and cytoprotective properties of LGG, in vivo and in vitro, following challenge with the 
pro-apoptotic agent, Staurosporine (STS) [48]. LGG pretreatment decreased apoptosis in STS-induced 
intestinal epithelial IEC-6 cells and Caco-2 cells by significantly reducing terminal deoxynucleotidyl 
transferase (TUNEL) positivity. Moreover, LGG also inhibited intestinal epithelial apoptosis in 2-week 
old preweaned mice affected by STS. More importantly, it has been found that the inhibition of 
caspase 3 activity and regulation of anti-apoptotic genes largely contributed to the anti-apoptotic 
properties of LGG [48]. Further investigations demonstrated that LGG modulated apoptosis-related 
genes in a different manner compared to pathogenic Salmonella typhimurium [48,49]. LGG has been 
reported to regulate cellular proliferation and migration and mitogen-activated protein kinase  
(MAPK) pathways, which play a pivotal role in cell proliferation, differentiation and cytoprotection  
activities [48,50]. Furthermore, LGG was also reported to induce anti-apoptotic gene transcription 
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without up-regulation of proinflammatory genes, whereas S. typhimurium up-regulated anti-apoptotic 
genes by NF-κB activation [49]. Similar results recently reported by Yanagihara et al. illustrated that 
the expression of genes related to cell proliferation was amplified after exposure of human 
gastrointestinal epithelial Caco-2 cells to the probiotic Lactobacillus acidophilus 92 for 20 h [51]. 
During the same treatment, it was also found that cell proliferation and gene regulation were associated 
with MAP kinase linked to changes in gene expression for the G-protein coupled receptor, cytochrome 
P450 and zinc finger protein [51].  
2.4.2. Cell Apoptosis 
Apoptosis is a cell suicide mechanism to control cell numbers in tissues and eliminate individual 
cells [52]. However, unscheduled apoptosis of certain cells can be detrimental [52]. An increase in the 
apoptosis to proliferation ratio leads to bacterial invasion and toxin delivery in several diseases. 
Probiotics have the ability to prevent inflammation-induced cell apoptosis [53]. Yan and Polk reported 
that LGG was able to prevent cytokines such as TNF-α, IL-1α or γ-interferon inducing apoptosis in 
both mouse and human colonic epithelial cells [54]. The inhibitory effects of LGG on apoptosis were 
thought to be due to activation of the anti-apoptotic Akt/protein kinase B, and pro-apoptotic 
p38/mitogen-activated protein kinase [54]. Moreover, the probiotic strain of Saccharomyces boulardii 
prevented TNF-α induced apoptosis in enterohemorrhagic Escherichia coli infected human colonic 
T84 cells [55]. In the presence of S. boulardii, E. coli infected cells did not initiate the activation  
of some apoptotic features such as procaspase-3, poly-ADP-ribose polymerase (PAPR) and 
internucleosomal cleavage of DNA. Additionally in the same study, S. boulardii prevented the 
activation of caspases-9 and -8, which together led to the anti-apoptotic activities of S. boulardii 
against pathogens [55]. Similar results were obtained by Wang et al. who reported that the probiotic 
mixture, kefir, reduced ovalbumin induced apoptosis in mouse heart tissues by limiting levels of the 
pro-apoptotic proteins Bax and Bad, cytochrome c and caspase-3 [56]. Administration of probiotic 
mixtures also depressed expression of apoptosis linked proteins such as pro-apoptotic Bax, caspase-3 
and -8, and anti-apoptotic Bcl-2 in the livers of rats fed a methionine choline-deficient diet [57]. The 
ability of probiotics to modulate apoptotic and anti-apoptotic proteins has also been illustrated in 
acetaminophen-induced hepatotoxicity [58] and chemotherapy-induced small and large intestinal 
apoptosis in rats [59]. Furthermore, Clostridium butyricum can degrade non-digestible high amylose 
maize starch to butyrate and acetate. Butyrate (short-chain fatty acid), has been reported to inhibit 
carcinogenesis in the colon [60].  
Probiotics can therefore not only induce cell proliferation related gene expression to stimulate cell 
growth, but also modulate the apoptotic/anti-apoptotic proteins contributing to efficacy in response to 
cytokine mediated inflammation and apoptosis.  
2.5. Immunity 
Approximately 70% of the immune system is situated along the intestinal tract as GALT  
(gut-associated lymphoid tissue); a crucial component of the immune system [61]. A relationship 
between the intestinal microbiota and host immunity has been widely investigated [3,4,62,63] playing 
an important role in maintaining host immunity through activation of the immune response during 
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periods of stress, for example against pathogenic threats [6,61,64]. Dysbiosis of the endogenous 
microbiota can lead to compromised immune responses and contribute to the manifestation of diabetes 
and other autoimmune diseases [65]. Probiotic administration could be a worthwhile strategy  
to modulate a disordered intestinal ecosystem. Administration of certain probiotics can enhance 
immunity [13]. For instance, Moro-Garcia et al. reported that dietary supplementation with 
Lactobacillus delbrueckii subsp. bulgaricus 8481 for 6 months enhanced the immune response in 
elderly people, by increasing numbers of circulating NK cells and immature T cell subsets [13].  
In addition, the immune risk phenotype (IRP), characterized by an inverted CD4/CD8 ratio, an 
increase of CD8 + CD28
null
 T cells, and cytomegalovirus (CMV) infection, was also counteracted by 
this probiotic in a group of elderly people [13,66]. The mechanisms underlying probiotic effects on 
immunity will be discussed in the following sections. 
2.5.1. Immunoglobulin Responses  
Immunoglobulin A (IgA) is a major antibody that is secreted across intestinal mucosal linings, 
playing a critical role in mucosal immunity [67,68]. During pathogenic invasion, low numbers of 
commensal bacteria remain in intestinal Dendritic cells (DCs) for several days [67]. These  
commensal-loaded DCs are limited by the mesenteric lymph nodes (MLNs), and repeated intestinal 
commensal priming results in the production of IgA, selectively and locally, which is responsible for 
forming one layer of the mucosal barrier against bacterial penetration [67].  
To date, several studies, have demonstrated the effect of probiotic intake on improved host 
immunity via the production of IgA [21,69]. Qiu et al. in 2012 reported that one-day old broilers fed a 
diet containing Lactobacillus casei, Bifidobacterium bifidium, and Enterococcus faecium exhibited a 
more rapid rate of serum antigen specific IgG production and an increase in total IgA in the jejunum 
than those fed a control diet [69]. Yang et al. also reported enhanced serum levels of IgA, IgM and IgG 
in broiler chickens after being fed the probiotic Clostridium butyricum for 40 days [12]. More 
promisingly, serum levels of IgA, IgG and IgM of colorectal cancer patients who had undergone 
elective laparoscopic radical surgery, significantly increased after probiotic (Jinshuangqi Tablets, Inner 
Mongolia Shuangqi Pharmaceutical Co. Ltd., Hohhot, China), administration for 7 days [21].  
In the same study, serum IL-2 and CD4
+
 levels also significantly improved [21]. Together, these  
results reveal that candidate probiotics may improve the immune function of the host via modulation of  
antigen-specific antibodies.  
2.5.2. Inflammation 
A variety of probiotics, such as Lactobacillus spp., Enterococcus faecium JWS 833 and 
Faecalibacterium prausnitzii [70–72] have been reported to maintain immune homeostasis through 
modulating inflammation in DSS-induced colitis [34], alcohol-induced inflammation [70,73], 
cytokine-mediated gastrointestinal diseases [74], tumor bearing, and chemotherapy-induced  
mucositis in vivo, as well as pathogen infections in vitro [75]. For example, the probiotic  
Lactobacillus plantarum NCC1107 has been reported to reduce lung inflammation in mice by 
decreasing inflammatory cell numbers, eotaxin and IL-5 [76]. Moreover, dietary delivery of the 
probiotic Lactobacillus casei improved the immune response of mice bearing invasive ductal 
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carcinomas, through significantly increasing production of IL-12 and IFN-γ and increasing NK cell 
cytotoxicity in spleen cell cultures, and most importantly, reduced tumor growth rate [77]. 
Furthermore, administration of Clostridium tyrobutyricum depressed expression of TNF-α and IL-18 in 
the descending colon of DSS-treated mice [34]. Lactobacillus acidophilus A4 and its cell extracts have 
been shown to significantly decrease mRNA levels of IL-8, IL-1β, and TNF-α in pathogenic EHEC 
O157:H7 affected HT-29 intestinal epithelial cells in in vitro studies [78]. Recently, Lee et al. reported 
that the probiotic Lactobacillus rhamnosus GG attenuated lipopolysaccharide (LPS) induced 
inflammation of HT-29 cells by blocking TNF-α, and LPS induced IL-8 activation [79]. In in vitro 
studies, Lee et al. observed probiotic-induced down-regulation of the inflammatory pathway induced 
by LPS, including effects on NF-κB nuclear translocation, IkBa degradation and TLR4 mRNA [79]. 
Similarly, Wang et al. recently proposed that inflammation signaling induced by ovalbumin-affected 
allergy could be involved in increased TLR4 and subsequent activation of phospholate-Jun-N-terminal 
kinase (p-JNK), JNK1/2 (p-NFkB), p-IkB and TNF-α in the hearts of allergy-prone mice [56]. In 
contrast, a probiotic mixture composed mainly of lactic acid bacteria reversed this inflammation by 
restricting inflammatory signaling pathways [56].  
2.5.3. Dendritic Cells and Other Host Immune Responses 
Dendritic cells (DCs) are professional antigen-presenting cells, which normally remain in an 
immature stage in peripheral tissues [80,81]. They can be activated by contact with an antigen, such as 
a bacterium, resulting in initiation of the maturation process, and subsequently functional changes to 
the DCs [81]. Furthermore, DCs have an important role in regulating innate and adaptive immune 
responses by producing cytokines and chemokines [82]. Thus, it is worthwhile to investigate  
pathways of probiotics and pathogens in stimulating DC maturation in relation to cytokine and  
chemokine secretion.  
Commensal bacteria, such as Lactobacillus rhamnosus, and pathogenic bacteria, such as 
Streptococcus pyogenes, express similar molecular patterns [81]. However, they both induce immune 
responses through DC maturation and production of type I T helper cells (Th1) cytokines and 
chemokines in a different way [81]. Indeed, pathogenic S. pyogenes was able to induce TNF-α, IL-2, 
IL-12, IL-23, IL-27, CCL5, CCL19, CCL20, CXCL9 and CXGL10 in human monocyte-derived DCs 
indicating that this pathogenic bacterium is likely to create cytokine and chemokine environments that 
polarize the adaptive immune response toward Th1 type and induce inflammation [81]. In contrast, 
Lactobacillus rhamnosus induced a cytokine and chemokine (TNF-α and CCL20) response in DCs, 
which was significantly lower than S. pyogenes. Additionally, L. rhamnosus was unable to induce 
expression of inflammatory cytokines such as IL-2, IL-12, IL-23 or IL-27. Together, these results 
suggest that DCs have the capacity to distinguish pathogenic and non-pathogenic bacteria and respond 
to them differently, which in turn may result in the development of distinct adaptive immune  
responses [81].  
Certain probiotics have the capacity to stimulate DCs to produce anti-inflammatory cytokines while 
decreasing levels of pro-inflammatory cytokines induced by pathogens. A new probiotic strain, 
Lactobacillus paracasei CNCM I-4034 isolated from feces of breast-fed newborn infants, secretes 
bacterial compounds which can be identified by innate pattern-recognition receptors (PRRs),  
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in particular through TLR signaling [83]. L. paracasei CNCM I-4034 also reduced enteropathogenic 
(Salmonella typhi)-induced pro-inflammatory cytokine (IL-8, IL-6 and TNF-α) and chemokine  
(MCP-1, CCL2, RANTES and CCL5) production. Furthermore, L. paracasei CNCM I-4034 increased 
the secretion of the anti-inflammatory cytokine, transforming growth factor beta (TGF-β2), in human 
DCs, contributing to a reduction of inflammation [83]. Bifidobacterium breve UCC2003 produces a 
cell-surface-associated exopolysaccharide (EPS), linked to the evasion of adaptive B-cell responses, 
and believed to facilitate various aspects of a commensal-host interaction, as well as reduced 
colonization levels of the gut pathogen Citrobacter rodentium in vivo [84]. O’Callaghan et al. reported 
that L. salivarius UCC118 has the capacity to stimulate the expression of genes, such as CCL20, 
CXCL1, CXCL2, TNFAIP3, NFKBIA and BIRC3 in contact with Caco-2 cells. These genes are able 
to depress inflammation via down-regulating NF-κB and reducing cytokine-induced apoptosis [31]. 
2.5.4. Inflammasomes 
In a recent commentary, Howarth proposed that probiotics/prebiotics could modulate  
intestinal inflammation, immune response and function through an effect on inflammasomes [85]. 
Inflammasomes are a group of protein complexes built around several proteins including NLRP3, 
NLRC4, AIM2 and NLRP6 [86]. Inflammasomes can identify a wide range of microbial, stress and 
damage signals, and following the activation of capase-1 subsequently induce the secretion of  
pro-inflammatory cytokines such as IL-1 and IL-18 [86]. Miettinen et al. reported that nonpathogenic 
Lactobacillus rhamnosus could activate inflammasome functions and enhance antiviral activity in 
human macrophages [87]. Two L. rhamnosus strains, LGG and LC705, have been demonstrated to 
activate inflammasomes and as a result, stimulate levels of IL-1β in macrophages which are essential 
for caspase-1 activity [87]. However, it is unclear which inflammasomes are involved in the 
stimulation of IL-1β secretion [87]. Furthermore, in the same study, LC705 showed antiviral activity 
by inducing type 1 interferon-gene activation, associated with influenza A virus replication and viral 
protein production in macrophages [87]. However, in contrast, Strowing et al. concluded that 
inflammasomes can induce pyroptosis, a form of cell death, whilst inflammasome-mediated processes 
play an important role in microbial infections, regulation of metabolic processes, and mucosal immune 
responses in human diseases [86]. Indeed, a recent study by Qu et al. found that inflammasome 
NLRC4 phosphorylation (NLRC4 phospho-Ser 533) successfully inhibited the activation of caspase-1 
and pyroptosis in response to Salmonella typhimurium infection [88]. NLRC4 phosphorylation could 
therefore be a decisive point for NLRC4 inflammasome activation and host innate immunity [88].  
Further clarification of the role of inflammasomes and their modulation of intestinal inflammation, 
immune responses and gut function is required before we can understand the impact of probiotics and 
prebiotics on inflammasome-mediated processes.  
2.6. Safety  
Probiotics are commonly considered to be human-friendly and non-pathogenic bacteria. However, 
an awareness of safety implications should be maintained. Recent studies have found that the probiotic 
Escherichia coli Nissle 1917, a promising candidate for therapy against mucosal disorders [89,90], can 
induce DNA damage in vivo and trigger genomic instability and gene mutations in mammalian  
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cells [91,92]. This damage is involved in the development of colorectal cancer [91]. Furthermore, it 
has been reported that in the genome of E. coli Nissle 1917, a cluster of genes called “pks” island plays 
an important role in producing a hybrid peptide polyketide genotoxin, termed colibactin, which is 
responsible for genetic damage [91–93]. However, Olier et al. recently reported that the probiotic 
activity of E. coli Nissle 1917 should not be abolished by its genotoxic activity [14]. In their study,  
E. coli Nissle 1917 effectively reduced the colonic damage caused by DSS, with a decreased colitis 
score, decreased myeloperoxidase activity and pro-inflammatory cytokine IL-1β levels and increased 
IL-10 levels. However, E. coli Nissle 1917 has also been demonstrated to induce high levels of DNA 
double strand breaks in cultured intestinal crypt cells [14]. In another set of experiments Olier et al. 
tested the effect of an isogenic mutant of E. coli Nissle 1917 (Nissle ΔclbA) on DSS-induced colitis in 
rats and reported a disruption of the clbA gene and disabled activity of the pks island [14]. The Nissle 
ΔclbA mutant was unable to induce the same damage as wild type E. coli Nissle 1917. However, at the 
same time, the Nissle ΔclbA mutant also lost its probiotic function and did not have the capacity to 
reduce the severity of DSS-induced colitis, and in some cases, even exacerbated the damage [14]. 
Therefore, these results demonstrate that colibactin (from wild type E. coli Nissle 1917) could induce 
damage, but it may also play a pivotal role in the efficacy of E. coli Nissle 1917. Moreover, it is 
hypothesized that colibactin possesses anti-inflammatory activity and immunomodulatory functions. In 
addition, colibactin may consist of more than one molecule, which could be encoded by the 
biosynthetic gene clusters of the pks island, leading to its probiotic activity in the gut [14].  
Different strains of the same probiotic may also impart opposite effects, and results obtained from 
animal models could very well differ from those obtained in human studies. Further research is 
required to better identify the benefits and potential risks of probiotic administration. 
3. Probiotic-Derived Factors 
Overall, interest in investigating the impact of probiotics has grown steadily during the past decade, 
with most studies focusing on the mechanisms and clinical applications of probiotics associated  
with intestinal disorders in vivo and in vitro [17,18,94,95]. In contrast, the beneficial efficacy of  
probiotic-derived factors has been less documented, and only in recent years has there been an upsurge 
in research into the properties of probiotic-derived factors [74,96]. Further investigation of these 
factors could be used to achieve therapeutic benefits whilst avoiding risks related to the administration 
of live bacteria [20]. In addition, these factors hold potential for the development of safer therapeutic 
medicines, and provide a better understanding of the underlying mechanism of probiotics.  
3.1. Competition with Pathogens  
Several studies have revealed the capacity for probiotics to secrete probiotic factors, such as 
bacteriocins and reuterin, which have been shown to inhibit the adhesion and viability of known 
enteric pathogens [20,97]. These factors could be a rich source of new anti-pathogenic compounds that 
may play an important role in restricting the activities of pathogens. Lactobacillus reuteri formed 
biofilms that produced antimicrobial glycerol derivatives referred to as reuterin, which is a potent  
anti-pathogenic compound, and has been shown to inhibit a wide range of microorganisms [97,98]. 
Recently, Lactobacillus acidophilus ATCC 4356 has been reported to produce a proteinaceous 
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molecule which demonstrated inhibitory activity against eight of the human Campylobacter jejuni 
strains [99]. This suggests that Lactobacillus acidophilus ATCC 4356 has the potential to act as an 
antimicrobial agent for the treatment of Campylobacter infections in humans [99]. 
Moreover, Fayol-Messaoudi et al. reported that the probiotic strains Lactobacillus johnsonii La1, 
Lactobacillus rhamnosus GG (LGG), Lactobacillus casei shirota YIT9029, L. casei DN-114 001, and 
L. rhamnosus GR1 produced non-lactic acid molecules in their cell-free cultured supernatants [100]. 
These non-lactic acid molecules were believed to be responsible for killing activity against pathogenic 
Salmonella enterica serovar Typhimurium SL1344 [100]. During the same study, it was found that the 
reduction of pH in the culture media could have contributed to the restriction of Serovar typhimurium 
SL1344 growth in vitro [100]. It is equally important to note that, Lactobacillus johnsonii NCC 533 
isolated from human intestines, as well as eight different L. johnsonii strains and Lactobacillus gasseri 
were able to produce H2O2, under the conditions used to incubate these cells, and also in the presence 
of oxygen. More importantly, the supernatants from NCC 533, cultured in the presence of oxygen 
contained H2O2, which effectively killed the pathogen Salmonella enterica serovar Typhimurium 
SL1344 in vitro [101]. 
More recently, Gomes et al. found that Lactobacillus sakei 1 produced a heat-stable antimicrobial 
peptide (sakacin 1, a class IIa bacteriocin) in its culture supernatant [102]. This cell-free supernatant 
containing sakacin 1 exhibited the ability to reduce the chance of infection by the pathogen  
Listeria monocytogenes in human intestinal Caco-2 cells [102]. This ability is consistent with the 
inhibitory properties of probiotic Lactobacillus plantarum strain LP 31, which can also produce a 
bacteriocin that inhibits growth of pathogenic bacteria such as Pseudomonas spp., Staphylococcus 
aureus, Bacillus cereus and Listeria monocytogenes [103]. Moreover, supernatants from Bifidobacterium 
breve 46 and Bifidobacterium lactis 8:8 inhibited the growth and toxin production of Clostridium 
difficile (CD) NAP1/027 strain [104]. Seo et al. recently reported that the probiotic EcN can produce 
an antimicrobial defensin-mature fusion beta-defensin 2 (HisMHBD2) derivative in a soluble form [29]. 
This HisMHBD2 protein has demonstrated antimicrobial activity against the growth of Escherichia coli 
K-12 MG1655, Salmonella enterica serovar Typhimurium SL1344 and Listeria monocytogenes EGD. 
In addition, the recombinant EcN strain encoded a fusion protein containing YeBF gene, and the 
mature part of HisMHBD2 resulting in the production of YebFMHBD2, which also exhibited a 
significant inhibition of the growth of E. coli, Salmonella and L. monocytogenes [29]. These results 
indicate that EcN-released proteins could exert antimicrobial efficacy against several pathogenic species. 
Combined, these derived factors, released from live probiotics, and found in their culture 
supernatants could have activities similar to their original “parent” probiotics. Supernatants from 
certain probiotics could potentially lower the likelihood of infection in the host and indirectly assist in 
maintaining intestinal integrity and immunity. 
3.2. Maintenance of Intestinal Integrity 
The improvement of intestinal barrier function can be modulated by certain probiotic species. For 
example, certain probiotics can decrease gut permeability, through strengthening of the gut barrier 
against pathogen invasion. Moreover, the gut barrier can also be influenced by modulation of the 
mucus layer and/or tight junctions [20]. In an in vitro study, Wang et al. recently reported that LGG 
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supernatants prevented alcohol-induced Caco-2 cell monolayer barrier dysfunction by ameliorating 
alcohol-induced decreases in epithelial cell resistance and increases in permeability [105].  
More recently, Wang et al. have reported the effects of LGG supernatant administration on  
alcohol-induced intestinal barrier and liver damage in mice [73]. The LGG supernatant restored the 
alcohol-induced reduction in ileum mRNA levels of claudin-1, thereby showing the capacity for  
LGG-released factors to alter tight junction proteins [73]. Moreover, during an alcohol challenge, the 
intestinal epithelial cells experienced an oxygen adaption process, characterized by the expression of a 
master transcription factor, referred to as hypoxia inducible factor (HIF). This HIF is involved in 
inducing mucin production, regulation of intestinal trefoil factor (ITF), and the activities of  
P-glycoproten (P-gp) and other nucleotide signaling, which together play an important role in intestinal 
integrity [73,106,107]. Meanwhile, LGG supernatant pretreatment has demonstrated the ability to 
modulate mRNA levels of ITF, P-gp and cathelin-related antimicrobial peptide (CRAMP) in the ileum 
area of alcohol-challenged mice to partially restore intestinal barrier function [73].  
Protein A20 expressed in human colon epithelial cell lines (HT-29) is crucial for the degradation of 
endocytic allergens by facilitating endosome/lysosome fusion, which in turn maintains the gut 
epithelial barrier [95]. Probiotic (Clostridium butyricum CGMCC0313-1)-derived proteins extracted 
from the culture supernatants were able to enhance expression of A20 in HT-29 cells, resulting in an 
enhanced barrier function [95].  
A number of studies have reported the mechanism of live probiotics acting on the intestinal barrier 
by modulating tight-junction proteins and mucin levels in vivo and in vitro [22,25,35]. Evidence is still 
lacking for probiotic-derived factors to modulate the gut barrier in this context, although studies in  
in vitro models are underway.  
3.3. Cell Kinetics 
Several attempts have been made to investigate the effects of probiotic-derived factors on apoptosis 
in vitro [74,108,109]. A recent study by Prisciandaro et al. reported that supernatants from EcN and 
LGG significantly lowered the caspase activity of 5-FU challenged IEC-6 cell lines, suggesting their 
potential ability to prevent or inhibit enterocyte apoptosis induced by 5-FU [108]. The anti-apoptosis 
properties of probiotic LGG supernatants perhaps be explained by Yan et al. who identified 2 novel 
proteins, p75 (75 kDa) and p40 (40 kDa), both of which have been shown to play pivotal roles in 
reducing TNF-α-induced epithelial cell (Human and Mouse colon epithelial cells and cultured colon 
explants) apoptosis and importantly, promote the growth of these epithelial cells [74]. Moreover, p75 
and p40 were also found to be responsible for Akt activation by LGG released factors [74]. Together, 
these results suggest a promising application for the prevention of cytokine-mediated gastrointestinal 
diseases by using LGG-derived proteins.  
A recent study by Lebeer et al. further specified the functions of p75, renamed as Msp1, secreted by 
LGG [110]. These investigators reported that Msp1 is an O-glycosylated protein which can be 
glycosylated with mannose-specific Concanavalin A (ConA) reactive sugars at serine residues of  
106 and 107. Glycosylation for Msp1 is hypothesized to be involved in various glycan-mediated 
interactions of LGG, such as targeting specific innate immune cells and food degradation by  
microbes [110,111]. The investigation of protein glycosylation in probiotics could play an important 
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role in understanding the signaling process between the microbe and host, as these signaling pathways 
can be mediated by glycans through specific protein glycosylation [110]. This study suggested that a 
species-specific glycosylation mechanism for Msp1 could occur in different L. rhamnosus bacteria, 
which implies that the released factors from other probiotics could be glycosylated at other sites with 
other sugars. Additional research is required to thoroughly characterize the O-glycans and exact 
glycosylation sites of Msp1 [110] and also to identify other possible glycosylated proteins released 
from probiotics and their effects on glycan-mediated signaling pathways in response to disease or 
under normal conditions. 
3.4. Immunity 
3.4.1. Inflammation 
In recent years the number of studies investigating the effects of probiotic-derived factors  
on pathogen-induced or oxidative stimuli-induced inflammation has increased. For example,  
Lactobacillus reuteri-formed biofilms have the ability to suppress human TNF production in  
LPS-activated monocytoid cells [98]. In addition, Bifidobacterium breve and Streptococcus thermophilus 
have the ability to release metabolites (<3000 Da) which inhibit TNF-α secretion from 
lipopolysaccharide (LPS) affected peripheral blood mononuclear cells or the THP-1 cell line [75]. In 
addition, Menard et al. suggested that this anti-inflammatory effect (anti-TNF-α) was partially a result 
of the ability of B. breve and S. thermophilus released factors to suppress LPS-FITC (a fluorescent 
marker for detection by flow cytometry) binding to THP-1 cells, and also to inhibit NFκB  
activation [75]. Moreover, Caco-2 cells pre-treated with spent culture supernatants of Lactobacillus 
plantarum 2142 for one hour were able to inhibit the growth of Salmonella enteritidis 857 [112].  
In this study it was also found that spent culture supernatants decreased levels of IL-8 synthesis, and in 
addition, induced the expression of Heat-shock protein (Hsp) 70 in S. enteritidis 857 infected Caco-2 
cells [112]. These results demonstrated that L. plantarum 2142-released factors could exert  
anti-inflammatory effects by depressing IL-8 secretion and indirectly increasing levels of Hsp70 [112]. 
Recently, Paszti-Gere et al. reported the ability of L. plantarum 2142 SCS to significantly decrease 
pro-inflammatory IL-8 and TNF-α levels in porcine IPEC-J2 enterocytes in response to oxidative 
stress (H2O2) [96]. In addition, during the same experiment, Hsp70 gene expression was also 
significantly promoted, which demonstrated the importance of Hsp70 in response to oxidative or other 
stresses [96]. Importantly, L. plantarum 2142-specific proteins (21 and 31 kDa molecular weight) 
identified from spent culture supernatants of L. plantarum 2142, could be potential bioactive molecules 
for modulating inflammation and oxidative stress effected by various stimuli or diseases [96]. 
Probiotic-derived factors could therefore exert similar effects to their living probiotic counterparts by 
modulating chemotactic cytokine secretion and reducing inflammation resulting from pathogen 
invasion or intestinal disorders. 
3.4.2. Dendritic Cells 
Recently, it has been reported that probiotic Lactobacillus paracasei CNCM I-4034 cell free 
supernatants showed similar effects to live probiotic Lactobacillus paracasei CNCM I-4034, at 
Nutrients 2013, 5 72 
 
 
reducing pro-inflammatory TNF-α and chemokine MCP-1 levels in human DCs challenged  
with enteropathogenic Salmonella [83]. These supernatants also acted as potent inducers of  
anti-inflammatory TGF-β1 in reaction to Salmonella. It was hypothesized that certain factors released 
from L. paracasei CNCM I-4034, such as bacteriocins, could play an important role [83]. However, 
the effects were unlikely to be caused by acidic compounds, as the probiotic supernatants were 
neutralized to pH 7.0 for use [83]. Both living probiotics and pathogens can stimulate DC maturation, 
resulting in the secretion of cytokines and chemokines [81]. However, it is still unclear whether 
probiotic-derived factors stimulate DC maturation differently compared to pathogens. 
3.4.3. Other Host Immune Responses 
In 2012, López et al. reported the importance of probiotic bacteria co-culture with epithelial cells. It 
was found that soluble factors could be secreted in the supernatant of Bifidobacterium bifidum 
LMG13195 after being previously co-cultured with HT29 cells [113]. These soluble factors play an 




 cells expressing 
chemokine receptor Treg markers in human peripheral blood mononuclear cells (PBMCs) [113]. 
However, the supernatants of Bifidobacterium strains cultured without contact with epithelial cells 
were unable to exert significant beneficial effects on PBMCs [113,114]. This gives rise to a new 
concept that the biological impact of probiotic-derived factors could be potentiated if the supernatants 
from the original live probiotics were previously co-cultured with epithelial cells. 
3.5. Anti-Carcinogenic Properties 
The potential utility of probiotic-derived factors in cancer therapy represents a new frontier. Fatty 
acids such as butyrate have demonstrated anti-carcinogenic properties and Clostridium butyricum 
produces high levels of butyrate. Cousins et al. in 2012 found that Propionibacterium freudenreichii 
ITG P9 strain fermented milk supernatants induced apoptosis of HGT-1 cancer cells in a time and dose 
dependent manner [109]. The features of apoptosis in cancer cells affected by P. freudenreichii 
fermented milk supernatants included condensed and fragmented chromation, DNA laddering and 
accumulation of cells in subG1 cell cycle phase, reactive oxygen species accumulation, mitochondrial 
transmemebrane potential disruption, caspase activation and cytochrome c release [109]. These results 
indicate that certain probiotic-derived compounds could exert a cytotoxic effect on cancer cells, and 
may synergistically assist the action of certain chemotherapy drugs, such as camptothecin, to kill 
cancer cells [109]. The strategy of using these probiotic-derived factors as a food supplement for the 
patient could potentially reduce the required dose of chemotherapy treatment for cancer. However, this 
concept requires further investigation. 
4. Conclusions and Future Directions 
Determining the precise composition of secreted products from probiotic bacteria is challenging, 
and will depend on species, strain, micro-environment and culture conditions. In addition, it is rare for 
any individual probiotic to act through a single mechanism, and its biological impact is influenced by 
factors including dose, frequency of administration, and the composition of the microbiota. Given the 
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enormous numbers of bacterial species, strains and sub-strains in the microbiota, the number of 
potential probiotics, and consequently, sources of probiotic-derived factors, is equally far-reaching. 
Considered together, future studies adopting a more targeted approach to the identification of probiotic 
biofactors could reveal a bright future for the clinical application of specific biofactors for a range of 
digestive disease conditions. 
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